Literature DB >> 8449013

Termination of second trimester pregnancy with sulprostone and mifepristone: a randomized double-blind placebo-controlled trial.

P C Ho1, H K Ma.   

Abstract

A prospective randomized double-blind placebo-controlled trial was conducted in 13 subjects to find out whether mifepristone treatment could facilitate termination of second trimester pregnancy by sulprostone. The women received either 600 mg oral mifepristone or placebo tablets 36 hours before the administration of intramuscular sulprostone 0.5 mg every 6 hours. The median interval between the administration of sulprostone and abortion in the mifepristone group (4.6 hours) was significantly shorter than that in the placebo group (20 hours). The amount of sulprostone required was also significantly less in the mifepristone group. There was no significant difference in the incidence of side effects or analgesic requirement between the two groups. We conclude that oral mifepristone is useful in facilitating termination of second trimester pregnancies by sulprostone.

Entities:  

Keywords:  Abortion, Drug Induced--indications; Abortion, Induced--side effects; Asia; Clinical Research; Clinical Trials; Demographic Factors; Developing Countries; Eastern Asia; Family Planning; Fertility Control, Postconception; Hong Kong; Population; Population Dynamics; Research Methodology; Research Report; Time Factors

Mesh:

Substances:

Year:  1993        PMID: 8449013     DOI: 10.1016/0010-7824(93)90085-l

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Use of intravenous sulprostone for the termination of pregnancy with fetal death in second and early third trimester of pregnancy.

Authors:  Anita K Mohan; Mariam Mathew; Syed G Rizvi
Journal:  Sultan Qaboos Univ Med J       Date:  2008-11

Review 2.  Medical methods for mid-trimester termination of pregnancy.

Authors:  Hajo Wildschut; Marieke I Both; Suzanne Medema; Eeke Thomee; Mark F Wildhagen; Nathalie Kapp
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.